Newsroom

Press Releases

November 8, 2022

Business Wire

Qnovia to Pursue UK Approval for Lead Asset QN-01 in Nicotine Replacement Therapy

September 28, 2022

Business Wire

Qnovia, Inc. Raises $17 Million in Series A Funding to Advance Its Inhalable Therapeutics Pipeline

September 13, 2022

Business Wire

Respira Technologies, Inc. Rebrands as “QNOVIA”; Adopts Qnovia, Inc. as Corporate Name

Media

February 24, 2023

Tobacco Reporter

Qnovia Raises $17 million for Nebulizer

January 8, 2023

Barron's

It’s Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer.

December 27, 2022

PharmaShots

Brian Quigley, CEO at Qnovia Shares his Views on Raising Series A Funding

December 19, 2022

Fierce Pharma

2023 forecast: The biopharma name changing craze and the shifting sands of corporate branding

December 16, 2022

Richmond Biz Journals

Qnovia aims to bring smoking cessation medical device to market in 2025

December 16, 2022

MediaPost

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

December 16, 2022

Flipboard

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

December 13, 2022

PharmaShots

Brian Quigley, CEO at Qnovia Shares Insights on Respira Technologies Rebranded as Qnovia

November 16, 2022

Pharmaphorum

Health Innovators – Brian Quigley and Mario Danek (Live from HLTH 2022)

February 24, 2023

Qnovia Raises $17 million for Nebulizer

January 8, 2023

It’s Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer.

December 27, 2022

Brian Quigley, CEO at Qnovia Shares his Views on Raising Series A Funding

December 19, 2022

2023 forecast: The biopharma name changing craze and the shifting sands of corporate branding

December 16, 2022

Qnovia aims to bring smoking cessation medical device to market in 2025

December 16, 2022

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

December 16, 2022

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

December 13, 2022

Brian Quigley, CEO at Qnovia Shares Insights on Respira Technologies Rebranded as Qnovia

November 16, 2022

Have a Project in Mind? Say Hi!

Newsroom

Press Releases

Qnovia to Pursue UK Approval for Lead Asset QN-01 in Nicotine Replacement Therapy

Qnovia, Inc. Raises $17 Million in Series A Funding to Advance Its Inhalable Therapeutics Pipeline

Respira Technologies, Inc. Rebrands as “QNOVIA”; Adopts Qnovia, Inc. as Corporate Name

Media

Qnovia Raises $17 million for Nebulizer

It’s Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer.

Brian Quigley, CEO at Qnovia Shares his Views on Raising Series A Funding

2023 forecast: The biopharma name changing craze and the shifting sands of corporate branding

Qnovia aims to bring smoking cessation medical device to market in 2025

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

Brian Quigley, CEO at Qnovia Shares Insights on Respira Technologies Rebranded as Qnovia

Health Innovators – Brian Quigley and Mario Danek (Live from HLTH 2022)

Qnovia Raises $17 million for Nebulizer

It’s Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer.

Brian Quigley, CEO at Qnovia Shares his Views on Raising Series A Funding

2023 forecast: The biopharma name changing craze and the shifting sands of corporate branding

Qnovia aims to bring smoking cessation medical device to market in 2025

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

Brian Quigley, CEO at Qnovia Shares Insights on Respira Technologies Rebranded as Qnovia

Health Innovators – Brian Quigley and Mario Danek (Live from HLTH 2022)

Address:

Contact us

Investor Relations:

Media Relations:

Links